Differential pharmacological effects of antimuscarinic drugs on heart rate: A randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants ≥50 years

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 13, Issue 4, 2008, Pages 241-251

  Olshansky, Brian ^a   Ebinger, Ursula ^b   Brum, José ^c   Egermark, Mathias ^b   Viegas, Andrea ^b   Rekeda, Ludmyla ^b  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

Antimuscarinic; Darifenacin; Heart rate; Overactive bladder; Tolterodine

Indexed keywords

DARIFENACIN; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; TOLTERODINE;

ADULT; ANOREXIA; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSPEPSIA; DYSURIA; FEMALE; HEART PALPITATION; HEART RATE; HOLTER MONITORING; HUMAN; HUMAN EXPERIMENT; MALE; MULTICENTER STUDY; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; XEROSTOMIA;

AGE FACTORS; AGED; AGED, 80 AND OVER; BENZHYDRYL COMPOUNDS; BENZOFURANS; CONSTIPATION; CRESOLS; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; PROSPECTIVE STUDIES; PYRROLIDINES; TIME FACTORS; XEROSTOMIA;

EID: 57649173662     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/1074248408325404     Document Type: Article

References (32)

1. Abrams P., Cardozo L., Fall M., et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002 ; 21: 167-178.
2. Andersson KE Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004 ; 3: 46-53.
3. Wang P., Luthin GR, Ruggieri MR Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J Pharmacol Exp Ther. 1995 ; 273: 959-966.
4. Chess-Williams R., Chapple CR, Yamanishi T., Yasuda K., Sellers DJ The minor population of M3 receptors mediate contraction of human detrusor muscle in vitro. J Auton Pharmacol. 2001 ; 21: 243-248.
5. Stevens LA, Chapple CR, Chess-Williams R. Human idiopathic and neurogenic overactive bladders and the role of M2 muscarinic receptors in contraction. Eur Urol. 2007 ; 52: 531-538.
6. Fetscher C., Fleichman M., Schmidt M., Krege S., Michel MC M3 muscarinic receptors mediate contraction of human urinary bladder. Br J Pharmacol. 2002 ; 136: 641-644.
7. Abrams P., Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 2006 ; 148: 565-578.
8. Nelson CP, Gupta P., Napier CM, Nahorski SR Functional selectivity of muscarinic receptor antagonists for inhibition of M3-mediated phosphoinositide responses in guinea pig urinary bladder and submandibular salivary gland. J Pharmacol Exp Ther. 2004 ; 310: 1255-1265.
9. Andersson KE, Olshansky B. Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations. BJU Int. 2007 ; 100: 1007-1014.
10. Wang H., Han H., Zhang L., et al. Expression of multiple subtypes of muscarinic receptors and cellular distribution in the human heart. Mol Pharmacol. 2001 ; 59: 1029-1036.
11. Napier C., Gupta P. Darifenacin is selective for the human recombinant M3 receptor subtype [abstract 445]. Annual Meeting of the International Continence Society, Heidelberg, Germany. 2002. Available at: http://www.icsoffice.org/ publications/2002/PDF/445.PDF.
12. Olshansky B., Foote J., Arguinzoniz M., Lheritier K., Quebe-Fehling E., Steel M. The effects of darifenacin and tolterodine on heart rate (HR) in patients with overactive bladder (OAB) [abstract 124]. Annual Meeting of the International Continence Society, Christchurch, New Zealand. 2006. Available at: https://www.icsoffice.org/publications/2006/pdf/0124.pdf.
13. Fox K., Borer JS, Camm AJ, et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol. 2007 ; 50: 823-830.
14. Lanza GA, Fox K., Crea F. Heart rate: a risk factor for cardiac diseases and outcomes? Pathophysiology of cardiac diseases and the potential role of heart rate slowing. Adv Cardiol. 2006 ; 43: 1-16.
15. Hozawa A., Ohkubo T., Kikuya M., et al. Prognostic value of home heart rate for cardiovascular mortality in the general population: the Ohasama study. Am J Hypertens. 2004 ; 17: 1005-1010.
16. Aronow WS, Ahn C., Mercando AD, Epstein S. Association of average heart rate on 24-hour ambulatory electrocardiograms with incidence of new coronary events at 48-month follow-up in 1,311 patients (mean age 81 years) with heart disease and sinus rhythm. Am J Cardiol. 1996 ; 78: 1175-1176.
17. Irwin DE, Milsom I., Hunskaar S., et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006 ; 50: 1306-1314.
18. Milsom I., Abrams P., Cardozo L., Roberts RG, Thuroff JW, Wein AJ How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001 ; 87: 760-766.
19. Stewart W., Herzog R., Wein A., et al. Prevalence and impact of overactive bladder in the US: results from the NOBLE program. Neurourol Urodyn. 2001 ; 20: 406-408.
20. Task force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability. Eur Heart J. 1996 ; 17: 354-381.
21. Andersson KE, Kahler K., Ebinger U. Prevalence of cardiovascular comorbidities in patients treated with antimuscarinics for overactive bladder (OAB) [abstract 40]. Neurourol Urodyn. 2007 ; 26: 653-654.
22. Andersson KE, Kahler K., Ebinger U. Heart rates in OAB patients prior to initiation of treatment with antimuscarinics [abstract 41]. Neurourol Urodyn. 2007 ; 26: 654-655.
23. Ikeda T., Yusu S., Nakamura K., Yoshino H. Risk stratification for sudden cardiac death. Circ J. 2007 ; 71 (suppl A). A106 - A114.
24. Lahiri MK, Kannankeril PJ, Goldberger JJ Assessment of autonomic function in cardiovascular disease: physiological basis and prognostic implications. J Am Coll Cardiol. 2008 ; 51: 1725-1733.
25. Fisher JT, Vincent SG, Gomeza J., Masahisa Y., Wess J. Loss of vagally mediated bradycardia and bronchoconstriction in mice lacking M2 or M3 muscarinic acetylcholine receptors. FASEB J. 2004 ; 18: 711-713.
26. Haab F., Stewart L., Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol. 2004 ; 45: 420-429.
27. Hill S., Khullar V., Wyndaele JJ, Lheritier K. Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. Int Urogynecol J Pelvic Floor Dysfunct. 2006 ; 17: 239-247.
28. Romanzi LJ, DelConte A., Kralidis G. Impact of darifenacin compared with tolterodine on incontinence episodes in patients with overactive bladder [abstract 3522]. Obstet Gynecol. 2005 ; 105: 88S.
29. Steers W., Corcos J., Foote J., Kralidis G. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. BJU Int. 2005 ; 95: 580-586.
30. Rentzhog L., Stanton SL, Cardozo L., Nelson E., Fall M., Abrams P. Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. Br J Urol. 1998 ; 81: 42-48.
31. Choi JB, Kim YB, Kim BT, Kim YS Analysis of heart rate variability in female patients with overactive bladder. Urology. 2005 ; 65: 1109-1113.
32. Hubeaux K., Deffieux X., Ismael SS, Raibaut P., Amarenco G. Autonomic nervous system activity during bladder filling assessed by heart rate variability analysis in women with idiopathic overactive bladder syndrome or stress urinary incontinence. J Urol. 2007 ; 178: 2483-2487.